Balchem Corporation posted Q2 results, with EPS of $1.49 beating estimates by $0.07, while surpassing the consensus by $15M and was up 11% YoY. All areas of the business posted impressive results, as the minimum revenue growth for a segment was 8.9%, while the peak was 15% in Animal Nutrition & Health. The stock appears to be trading for a ~9% discount to its fair value right now based on my FCF valuation model.
Balchem Corporation (BCPC) Q2 2026 Earnings Call Transcript
Balchem Corporation (BCPC) Q1 2026 Earnings Call Transcript
| Specialty Retail Industry | Consumer Discretionary Sector | Theodore L. Harris CEO | XDUS Exchange | US0576652004 ISIN |
| US Country | 1,379 Employees | 23 Dec 2025 Last Dividend | 21 Jan 2010 Last Split | 3 Jun 1986 IPO Date |
Balchem Corporation is a leading company in the development, manufacturing, and marketing of specialty performance ingredients and products, catering to a diverse range of industries globally. Since its inception in 1967, Balchem has been dedicated to serving the nutritional, food, pharmaceutical, animal health, plant nutrition, industrial markets, and medical device sterilization. The company operates through three business segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products, ensuring a comprehensive approach to innovation and customer service. With its headquarters in Montvale, New Jersey, Balchem aims to leverage its extensive expertise to advance health, nutrition, and safety across various applications worldwide.
Balchem Corporation offers a wide variety of products and services across its diversified segments:
Balchem sells its diverse range of products through a combination of its sales force, independent distributors, and sales agents, ensuring a broad reach and efficient delivery to its global customer base.